The Covid-19 recurring business is expected to include boosters and shots against variants, like the flu, says Hartaj Singh, Equity Analyst at Oppenheimer & Co. he reviews the Biden Administration’s Covid booster shot program. He then talks about vaccine stocks, such as Pfizer (PFE) and Moderna (MRNA). Oppenheimer has a perform rating on Moderna. Tune in to find out more.
Morning Trade Live
19 Aug 2021
SHARE
Morning Trade Live
04 Aug 2022
Morning Trade Live
19 Aug 2022
Market On Close
14 Jun 2022
Morning Trade Live
08 Jun 2022
The Watch List
19 May 2022
The Watch List
15 Jul 2022